Long-Term Real-World Safety of Cobenfy in Adults With Schizophrenia
← catalyst calendarNCT07783373 · readout in 397 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
3,000estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-24
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-01 | actual | When the study began enrolling |
| Primary completion | 2027-09-26 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-04-26 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Schizophrenia
Interventions
- Drug: xanomeline-trospium chloride
- Drug: Oral antipsychotics
Primary outcome
what the primary-completion date above is the date OFNumber of participants with incident urinary retention
measured Up to 3-years
Related
BMY · their whole pipeline · Schizophrenia readouts · Congress trades in BMY · Executive-branch trades in BMY
BMY's other studiesmost recently updated first
- A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma Phase 3 · Completed
- A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Phase 3 · Not yet recruiting
- A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder Phase 3 · Not yet recruiting
- A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis Phase 1/2 · Recruiting
- Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02) Phase 3 · Not yet recruiting
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed